{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001658551","name":"Amylyx Pharmaceuticals, Inc.","summary":"Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapies for endocrine conditions and neurodegenerative diseases. Its lead asset is avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 (LUCIDITY trial) for post-bariatric hypoglycemia. Additional pipeline includes AMX0035 (Wolfram syndrome, Phase 2), AMX0114 (ALS, Phase 1), and AMX0318 (PBH, preclinical), all targeting high unmet medical needs with no currently approved therapies.","people":[],"products":[{"name":"Avexitide","type":"service","description":"First-in-class GLP-1 receptor antagonist in Phase 3 for post-bariatric hypoglycemia (PBH) and Phase 2 for congenital hyperinsulinism; FDA Breakthrough Therapy Designation for both indications."},{"name":"AMX0035","type":"service","description":"Oral fixed-dose combination of sodium phenylbutyrate and taurursodiol targeting ER stress and mitochondrial dysfunction; in Phase 2 for Wolfram syndrome with positive Week 48 data."},{"name":"AMX0114","type":"service","description":"Investigational antisense oligonucleotide targeting calpain-2 (CAPN2) for ALS; in Phase 1 LUMINA trial with intrathecal administration, first participant dosed April 2025."},{"name":"AMX0318","type":"service","description":"Novel long-acting GLP-1 receptor antagonist selected as development candidate in January 2026 for PBH and other rare diseases."}],"partnerships":[{"partner_name":"Breakthrough T1D","partnership_type":"development","description":"Breakthrough T1D funds University of Washington and Amsterdam UMC trial of AMX0035 for insulin resistance in type 1 diabetes; Amylyx provides clinical trial supply.","start_date":null},{"partner_name":"University of Washington","partnership_type":"development","description":"Externally-sponsored research site investigating AMX0035 as adjunctive therapy for insulin resistance in type 1 diabetes, funded by Breakthrough T1D.","start_date":null},{"partner_name":"Amsterdam University Medical Center","partnership_type":"development","description":"Externally-sponsored research site investigating AMX0035 as adjunctive therapy for insulin resistance in type 1 diabetes, funded by Breakthrough T1D.","start_date":null}],"affiliations":[],"origin":{"leaf":"cf61b9a0e6c19bd502b9bc7a49c75953e124e1b131cb8391cb8e6bad4aaf0437","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"36e9d538f31223827c7eda9728685109485685b98e8e78d9893bde59bdb41ffa","parent":"9ed923365072a85744385449523046c4fc7635a9c8f3119c1b2e7e80f1b7dc9a","source":"0001193125-26-086645","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":451,"hourly_limit":500,"remaining":49,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}